Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Rituximab 66Cyclophosphamide 46Vincristine 40Doxorubicin 40Prednisone 35Etoposide 19Radiotherapy 14Gemcitabine 13Peripheral Blood Stem Cell Transplantation 12Filgrastim 12Cytarabine 12Lenalidomide 11Carmustine 10VAP-cyclo protocol 9Prednisolone 9Oxaliplatin 9Melphalan 9Methotrexate 7Ifosfamide 7Mitoxantrone 6Bleomycin 6polatuzumab vedotin 5R-CHOP protocol 4Methylprednisolone 4Injections 4Granulocyte Colony-Stimulating Factor 4Cyclosporine 4Cisplatin 4Carboplatin 4pegfilgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Large B-Cell, Diffuse × Biological Therapy × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡